Mike Putman
Publishes 1 feed
Autoimmune Drug Development Report
What's coming, what just landed, and where the industry is getting it wrong — a rheumatologist's take on autoimmune drug development.
18 posts · theirs
Lately
Stop Immunology-ing Cardiology
EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO)
NEJM Retracts Avacopan
EBR Journal Club: Obexelimab in IgG4-Related Disease (INDIGO)
EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH)
“Peptides,” BPC-157, and the Mainlining of Pseudoscientific Nonsense
The (sc)Pen is Mightier Than the (iv)Cord
Re-Adjudicating Avacopan
EBR Journal Club: Ixekizumab + Tirzepatide in Psoriatic Arthritis (TOGETHER-PsA)
The CAR-T Landscape in Autoimmune Disease
EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR)
Critical Commentary: Run Fewer Phase 2 Trials
Everything on this page was read from markup Mike Putman published — a rel="me" link, an h-card, or the feed’s own author element. Nothing was inferred from anywhere else. To correct or remove it, get in touch. Machine-readable: JSON